AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Description: GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
Study NCT01826981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEL
Description: Velpatasvir (VEL) tablet(s) administered orally once daily
Study NCT02966132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMD
Description: Interactive video education delivered on a tablet computer
Study NCT02966132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NPA
Study NCT01352273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162 + RAF265
Study NCT02179047 — intervention group
Intervention type: PROCEDURE
Intervention: coronary angiography
Description: percutaneous coronary intervention. coronary angiography.
Study NCT00961779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
Study NCT00961779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline infusion
Study NCT04136483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
Study NCT02090777 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Coach
Study NCT00901615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and R-CHOP
Description: Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
Study NCT04030676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Two more biopsies in inflammatory zone will be collected.
Study NCT04030676 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
Study NCT00677313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metreleptin
Description: metreleptin injection
Study NCT03479008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Therapeutic Vibration Device
Description: The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
Study NCT03014271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sources of Strength (SOS) Prevention Program
Description: Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
Study NCT03014271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sources of Strength (SOS) Prevention Program
Description: Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
Study NCT01666912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Contraceptive implant
Study NCT01666912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive implant
Study NCT01229215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCFD4514S
Description: Repeating intravitreal injection
Study NCT01229215 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Repeating sham injection
Study NCT04403113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured neck and trunk stabilization exercises
Description: Intensive structured neck and trunk stabilization exercises based on Neurodevelopmental therapy method-Bobath concept principles. These exercises were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
Study NCT04403113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding and oral motor intervention strategies
Description: Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
Study NCT04403113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding and oral motor intervention strategies
Description: Feeding and oral motor intervention strategies program were performed for 6 weeks, 2 days a week, 45 minutes for a total of 12 sessions.
Study NCT04403113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caregiver training related to feeding
Description: In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
Study NCT04403113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caregiver training related to feeding
Description: In caregiver training related to feeding; a) positioning and feeding technique during feeding, b) ensuring safety for aspiration, c) using suitable containers and ingredients, d) adjusting (adapting) food consistency properly, e) preparing small amounts of high-calorie, balanced diet and f) reducing food spillage while feeding and how to ensure efficacy for shortening the feeding time, g) providing appropriate postural and physical support for self-feeding. All of these activities were continued for 6 weeks with a home program.
Study NCT03619655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT CT
Description: MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
Study NCT03619655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
Study NCT03619655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-NaF PET/CT
Description: A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
Study NCT03619655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WB-MRI
Description: Whole body MRI exam (total examination time \< 50 minutes)
Study NCT01877668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Description: Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
Study NCT01877668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Description: Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
Study NCT01877668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
Study NCT01877668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
Study NCT01877668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
Study NCT01792765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Description: Patient will have intraoperative ultrasound .
Study NCT03289988 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
Study NCT00731796 — intervention group
Intervention type: DEVICE
Intervention: Functional Outcome Measure
Description: Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
Study NCT01569945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomifen, Ethinyl Estradiol
Description: starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
Study NCT01569945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menotropins
Description: Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
Study NCT02014519 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: A blood sample (2.5 mL) will be collected from all subjects
Study NCT02014519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Active questioning
Study NCT01957579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
Study NCT01473940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Given IV
Study NCT01473940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01473940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00534248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live (Zostavax™)
Description: A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
Study NCT00534248 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
Study NCT03620526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
Study NCT03620526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
Study NCT02598739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension.
Study NCT02598739 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list for the exercises
Study NCT00423280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6R-BH4
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Study NCT00423280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 6R-BH4
Description: 6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
Study NCT01706835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aldoxorubicin
Study NCT00112918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administered as an intravenous infusion over 30 - 90 minutes.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Film-coated tablets
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Description: Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an intravenous infusion over 2 hours.
Study NCT00112918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an intravenous infusion over 2 hours.
Study NCT02421302 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RUTF
Description: This is ready-to-use-therapeutic-food
Study NCT02853526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TIPS
Description: Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
Study NCT02853526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
Study NCT02853526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
Study NCT02853526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
Study NCT02853526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
Study NCT03096561 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood draw from three different vessels
Description: Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
Study NCT01737411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Study NCT01737411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cesa/vasa
Description: surgical repair of USL
Study NCT01964989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
Description: 1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Study NCT01964989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Description: 1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to \<36 months, 0.5 ml: ≥36 months to \<72 months
Study NCT02517736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib at a dose of 800 mg / day
Study NCT03100656 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A breakfast sandwich
Description: A meat-based breakfast sandwich
Study NCT03176121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
Study NCT00447525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REVAXIS®
Study NCT00447525 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT-Polio®
Study NCT02061813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abametapir Lotion 0.74% w/w
Description: applied 0.2 mL topically under occlusive condition
Study NCT02061813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Lauryl Sulfate
Description: Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
Study NCT02061813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline 0.9%
Description: A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
Study NCT02061813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03934008 — intervention group
Intervention type: OTHER
Intervention: MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)
Description: The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.